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Oblectlves To determine the incidence, clinical presen-
tation, and outcome and confounding factors associ-
ated with the development of a brain abscess in solid or-
gan transplant recipients. 
Design: A 14-year retrospective survey. 
S.Hingl A Single, multiorgan, academic transplanta-
tion center. 
Patlentsl A total of 2380 liver transplant recipients, 1650 
kidney transplant recipients, and 598 heart. heart-lung, 
or lung transplant recipients of all ages (pediatric and 
adult) were included. All patients were given cyclosporine-
based immunosuppression during this period. 
Main Ouko .... M.asures A brain abscess was deter-
mined to be present if there was histological and/or mi-
crobiolOgical confirmation of a brain lesion seen by a com-
puted tomographic scan. A brain abscess was considered 
suspicious if radiographic findings were seen in the clini-
cal setting of neurologiC symptoms and fever without his-
tolOgical or microbiological confirmation. 
•• sulhl A brain abscess developed in a total of 28 pa-
tients (0.61%) of the total study population. The fre-
quency of brain abscess according to organ type was as 
follows: 0,63%, liver; 0.36%, kidney; and 1.17%. hean and 
heart-lung. The overall mortality was 86%. Complicating 
factors associated with fungal (Candida and Aspergillus sp) 
abscess formation included major subsequent opera-
tions, retransplantations, antirejection therapy, associ-
ated bacteremia or viremia, and multiorgan failure. The 
lung was the primary site of dissemination in 18 patients. 
Low-dose prophylactic amphotericin was ineffective in pre-
venting a fungal brain abscess in 10 high-risk patients. Be-
cause of the ineffective therapy and the deadly nature of 
established fungal abscesses. full-dose antifungal therapy 
and reduced immunosuppression were warranted on iden-
tification of a high-risk clinical setting. Nonfungal ab-
scesses (Nocardia and Toxoplasma sp) occurred in healthy 
graft recipients long after transplantation. The existing 
medical therapy is usually effective in these patients, pro-
vided that rapid tissue diagnosis is established. 
Conclusions: The epidemiological features of brain ab-
scess formation after solid organ transplantation sug-
gest 2 populations of patients exist that differ in timing, 
clinical setting, and response to therapy. For the chroni-
cally immunosuppressed outpatient, an established ab-
scess should be empirically treated with sulfonamides un-
til tissue diagnosis is confirmed. On the other hand, the 
acutely immunosuppressed posttransplant recipient, with 
defined risk factors, should receive full-dose therapy with 
amphotericin B and concomitantly lowered immuno-
suppression. 
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A BRAIN abscess is a focal suppurative process of variable size that devel-
ops within the brain pa-
renchyma and is sur-
rounded by an inflammatory exudate. In 
the immunocompetent host, brain ab-
scesses are usually bacterial. They con-
sist of a central area of necrotic debris and 
leukocytes with a fibroblastic capsule sur-
rounded by cerebritis and perivascular 
infiltrates. 
enous dissemination from a primary site 
of invasion. Microscopically, these are 
manifested by an arteritis with fungal 
thrombosis and obliteration of the vessel 
lumen prodUCing ischemic or hemor-
rhagiC infarcts. l This pattern of encepha-
lomalacia may result in solitary or mul-
tiple abscesses. Mortality among patients 
with brain abscesses who have not under-
gone transplantation can be as high as 25% 
in some series. 2 This study encompasses 
a 14-year period with a minimum 2-year 
follow-up of 4628 solid organ transplant 
recipients who have been receiving cyclo-
sporine-based immunosuppression after 
In the immunocompromised host, 
however, fungal brain abscesses predomi-
nate and usually originate as hematog-
PATIENTS AND METHODS 
PATIENT POPULATION 
A If-year retrospective review of all adult and pediatric pa-
tients who underwent liver (n=2380), kidney (n= 1650), 
and hean, hean-lung, or lung (n=598) transplantation was 
done to detennine the frequency and outcome of brain ab-
scesses in a solid organ tranSplantation population who were 
receiving cyclosporine therapy. All organ recipients were 
classified according to United Network Organ Sharing guide-
lines and selected based on medical urgency. 
SURGICAL TECHNIQUE 
Established techniques for multiple organ procurement were 
used in all cases. Standard surgical techniques for ortho-
topic liver, heart, double lung, heart-lung, and hetero-
'- topic kidney transplantations were performed.3 No single 
\ lung transplantations were done during this intervaL 
i IMMUNOSt;PPRESSION 
Liver and kidney recipients were given cyclosporine, 8 to 12 
mWkg per day, for induction therapy, then adjusted to main-
tain cyc\osporine concentrations of 750 to 1000 nglmL as 
measured by fluorescence polarization immunoassays (TDx, 
Abbott Diagnostic, Chicago, Ill). Methylprednisolone so-
dium succinate (l g for patients weighing ~PM kg and 500 
mg for those weighing <30 kg) was also given for induc-
tion therapy, followed by a 7 -day methylprednisolone taper 
for adults. The daily maintenance prednisone dose was 10 
mg for recipients weighing less than 30 kg and 20 mg for 
those weighing 30 kg and more. Acute cellular rejection was 
treated with 1 g of methylprednisolone sodium succinate 
andlor a corticosteroid taper and adjustment of the cyclo-
sporine dose. Resistant rejections were treated with mono-
clonal antibodies or muromonab-CD3 (Onhoclone OKT3, 
Ortho Phannaceutical Corp, Raritan, NJ), 5 mgld (adult dose) 
or 2.5 mgld (pediatric dose), for 7 to If days. 
Hem, lung, and hean-lung transplant recipients all re-
ceived a preoperative loading dose of cyclosporine orally, 17.5 
mWkg, and azathioprine sodium intravenously, 4 mglkg; in-
traoperatively, they received 1 g of methylprednisolone sodium 
succinate intravenously. Postoperatively, cyclosporine was ad-
justed to maintain a 12-hour trough with blood concentrations 
between 500 and 1000 nglmL (TDx). The heart transplant re-
cipients received a corticosteroid taper to a daily-maintenance 
prednisone dose of 15 to 20 mg. The heart-lung transplant re-
cipients did not receive corucosterOids for the first If days post-
operauvely to allow the tracheal anastomosis to heal. Dunng 
this time, they received a 3- to 5-<iay course of rabbit anti thy-
mocyte globulin andlor azathioprine sodium. I 102 mglkg per 
day. Acute cellular rejection was treated VI'ith I g of methyl-
prednisolone sodium succinate and a taper for the first reJec-
tion episode and WIth rabbIt anuthymocyte globulin or 
muromonab-CD3 for subsequent episodes. The postoperative 
course of all patients was observed up to January 1, 1995. 
transplantati9n at the University of Pittsburgh Medical 
Center. Pittsburgh, Pa. The clinical spectrum of brain ab-
scesses in the liver. kidney, and hean, lung, and hean-
lung transplant recipients is characterized. 
ANTIBIOTIC PROPHYLAXIS 
Selective bowel decontamination was not used in any of 
the transplant recipients during this period. Acyclovir and 
a combination of trimethoprim-sulfamethoxazole in ad-
justed doses were used as prophylaxis for herpesvirus and 
pneumocystic infections. Prophylactic systemic antibiot-
ics were used for 3 to 5 postoperative days. Liver trans-
plant recipients, for the last 7 years of the study, received 
a low dose of amphotericin B, 0.25 to 0.30 mglkg per day, 
as a prophylactic antifungal therapy when (1) operations 
lasted longer than 12 hours, (2) the primary nonftinction 
of the graft required retransplantation, and (3) multiple sub-
sequent operations were necessary. Therapy was gener-
ally continued for at least 2 weeks or for the duration of 
the patient's stay in the intensive care unit after identifica-
tion of the patient as high risk. 
DEFINITION OF A BRAIN ABSCESS 
A pyogenic brain abscess classically consists of a central 
area of necrotic debris and leukocytes surrounded by a dense 
fibroblastic capsule. Beyond this is a zone of cerebritis, neo-
vascularity, and edema. This appears on a computed to-
mographic (CT) scan as a hypodense region surrounded 
by an enhancing ring of uniform thickness with a periph-
eral area of hypodensity representing edema.) 
The cause of a brain abscess in patients who have un-
dergone transplantation is usually fungal. These abscesses 
have disseminated hematogenously from other sites and lead 
to arteritis with fungal thrombosis of the cerebral vessellu-
men (Figure 1). Solitary or multiple brain abscesses may 
arise from the resulting encephalomalacia. These areas of 
ischemic or hemorrhagic infarction are often not well en-
capsulated and can appear on a CT scan as nonspecific, low-
density lesions \\-ith minimal or no contrast enhancement 
(Figure 2). 
In this study, a brain abscess was determined to be pre-
sent if there was histological andlor microbiological con-
firmation of a brain lesion as seen by the CT scan. Speci-
mens were obtained during a stereotactic or open biopsy 
or at postmortem autopsy. A brain abscess was considered 
suspicious if radiographic findings were seen in the clini-
cal setting of neurologic symptoms and fever even if his-
tological or microbiological confirmation was absent. Posi-
tive CT findings included solitary or multiple low-density 
lesions \\-ith minimal contrast enhancements or areas of 
ischemic or hemorrhagic infarction as pre\'iously 
described. 
STATISTICAL ANALYSIS 
This is a retrospective review of all solid organ transplant 
recipients in whom a brain abscess developed dunng a 
If-year period. The clinical course of those in whom a 
brain abscess developed is described. A statistical com-
parison was impossible because of the large number of pa-
tients without a brain abscess. The results are given in de-
scriptive fonn. 
This study (1) defines the incidence and severity of 
brain abscesses in this population, (2) identifies pa-
tients at risk for the development of a brain abscess. 
(3) describes the clmical pattern and evolution of a brain 
Figure 1. ArteritIs with fungallhramlJasls of the cerebral vessel lumen. 
abscess . (of) examines the cause of the brain abscesses ac-
cording to allograft t~-pe I (5) assesses the efficacy of avail-
able treatment options, and (6 ) proposes other effective 
treatment methods. 
GENERAL 
During a 14-year period, there were 28 patients ""ith brain 
abscesses among 4628 transplant recipients for an over-
all prevalence of 0.61 %. Brain abscesses occurred in 0.63% 
of liver, 0.36% of kidney, and 1.17% of heart and/or lung 
transplant recipients. The average age (::+::5E) of affected 
patients was 36.5::+:: 2.8 years (range, 14 days to 66 years) 
with a male-female ratio of 1: 1. 
Fever (in 26 patients) , seizures (in 12 patients), and 
deterioration of mental status with progression to coma 
(in 12 patients) were the most common signs. Cytologi-
cal cerebrospinal fluid abnormalities were slight and non-
speCific, and all 22 cerebrospinal fluid cultures were ster-
ile. Eleven electroencephalograms were performed , 
shOwing epileptiform foci in 4 and slow waves or no cor-
tical activity in another 4; the electroencephalographic 
recordings were normal for 3 patients. Contrast-
enhanced CT scans of the head showed a Single abscess 
in 8 patients and multiple abscesses in 13 patients. Char-
acteristic CT scan findings of enhancing lesions were noted 
in 16 patients, and hemorrhagic infarctions were noted 
in 5 patients: 4 patients had a normal CT scan finding . 
All anatomical areas of the brain were represented in ab-
scess formation . 
Brain abscesses were confirmed by histological and/or 
microbiological isolation from autopsy (17 patients) , brain 
biopsy (7 patients), or maxillary sinus biopsy (2 pa-
tients) specimens. In 2 patients, the diagnosis of a brain 
abscess was clinical, based on a primary site of Aspergil-
lus sp lung infection and brain lesions on a CT scan. The 
diagnosis was made in 2 of the patients post mortem. All 
infections were caused by a fungus or Nocardia or Toxo-
plasma. There were no ty-pical pyogenic brain abscesses. 
With the exception of 3 patients with mixed isolates, all 
patients had abscesses with a single isolate . Hematog-
enous spread from the lung occurred in 18 of 28 cases, 
while an adjacent sinus infection caused the abscess in 
2 patients. Other sites of secondary dissemination, aside 
Figure 2. A computed tomographic scan of a brain abscess. 
from the liver, included the heart , thyrOid, spleen, kid-
neys, muscles, skin, pleura, and pericardium. 
LIVER 
Liver recipients in whom brain abscesses developed 
(n= 15) required augmented immunosuppression; 9 pa-
tients received at least one 7 -day course of muromonab-
CD3, and 11 received at least one additional corticoste-
roid bolus and/or taper. Associated bacteremia occurred 
in 11 recipients, and cytomegalOVirus viremia occurred 
in 5 recipients . The retransplantation ratio was 1.8 liv-
ers per patient, and 11 patients had poor initial graft func-
tion. All 15 patients were ventilator dependent beyond 
2 weeks; 12 had renal failure and were hemodialysis de-
pendent. In addition , 9liver reCipients underwent at least 
1 abdominal reexploration exclusive of transplanta-
tions. The reasons for the subsequent operation were intra-
abdominal hemorrhage in 7 patients, biliary reconstruc-
tion in 1 patient, and peri tonitis in 1 patient. Mortality 
was due to sepsis in all but 2 cases, in which it was di-
rectly related to hemorrhagiC complications of neuro-
surgical procedures (Table 1). 
Aspergillus sp were the most common organism 
found in the liver recipients (found in 13 of the 15 pa-
tients ), and these organisms were seen a median of 24 
days after transplantation. A mucormycosis infection oc-
curred in I ventilator-dependent liver transplant recipi-
ent "'ith poor initial graft function, an associated bacte-
rial infection, and prolonged leukopenia who required 
additional antirejection therapy. It involved the left fron-
tal and adjacent maxillary sinus with direct extension to 
brain tissue. The patient died of sepsis 37 days posttrans-
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Table 1. Clinical Characteristics of Brain Abscesses by Causative Agent* 
Causative Initial Graft Primary Site 
Alleat AIIDtraft Type Fundion of Infection 
Aspergillus sp (22) Uver (13); kidneys Poor (16), Lungs (17) 
(5); and heart good (6) and sinus (1) 
and heart-lung 
(4) 
Toxoplasma sp (2) Uver (1) Poor (0), Blood (2) 
and heart (1) good (2) 
Nocardia sp (2) Heart (2) Poor (0), Chest wall (2) 
good (2) 
Mucorales sp (1) Uver (1) Poor (1), Sinuses (1) 
good (0) 
Candida sp (1) Kidney (1) Poor (1), Lung (1) 
good (0) 
• The number in parentheses indicates the number of patients. 
tMedian. 
iMean. 
plantation despite receiving antifungal therapy. A brain 
abScess caused by Toxoplasma sp developed 62 weeks post-
transplantation in one patient with a functional graft and 
nO,other major risk factors (Table 2). 
HEART 
Brain and chest wall abscesses caused by Nocardia sp de-
veloped in 2 heart recipients with good primary graft func-
tion and no serious rejection episodes an average of 38 
weeks after transplantation. Both recovered after under-
going an aspiration biopsy and receiving antibiotic therapy 
(Table 1). 
A brain abscess caused by Toxoplasma sp devel-
oped 12 weeks posttransplantation in a hean recipient 
who was otherwise healthy and had an uneventful post-
operative course (Table 2). Unfortunately, he died be-
fore specific diagnosis and treatment of the brain ab-
scess were accomplished. 
A bram abscess caused by Aspergillus sp occurred 
in 4 heart or heart-lung recipients: these recipients had 
poor graft function (3 patients), bacteremia (3 pa-
tients), and cytomegalovirus or Epstem-Barr ViruS vire-
mia (l patient 1. were ventilator (all 4 patients) and he-
modialysis (3 patients) dependent. and required additional 
treatments of muromonab-CD3 and rabbit antithnno-
evte globulin (2 patients) Al14 patients died with ~edi­
cal management alone. 
KIDNEYS 
Four of 6 kidney transplant recipients in whom a brain 
abscess developed had failed allografts. with a retrans-
plant ratio of 1.3 kidnevs per patient. Five had major sub-
sequent operations, 2 for allograft nephrectomy and 1 each 
for intra-abdominal hemorrhage, gastrointestinal bleed-
ing. and colonic perforation. All 6 received additional cor-
ticosteroid boluses or taper. and 1 received muromonab-
CD3 for acute cellular rejection (Table 1). 
Associated bacteremia was present in 5 of the 6 pa-
tients. and cytomegalovirus viremia was noted in 2 pa-
Additional TIme From 
Aotirejection Transplantation 
Treatments Associated infection 10 DiagnOSis. d Outcome 
Corticosteroids (9); Bacteremia (17); 24t Dead (21). 
muromonaIrCD3 (15); viremia (8); a/Ive (1) 
and rabbit cytomegalovirus (9); 
antithymocyte and Epstein-Barr 
globulin (2) virus (1) 
Corticosteroids (0) and Bacteremia (0) and 26:1: Dead (2), 
muromonab-C03 (0) viremia (0) alive (0) 
Corticosteroids (0) and Bacteremia (1) and 267t • Dead (0). 
muromonab-C03 (0) viremia (0) alive (2) 
Corticosteroids (1) and Bacteremia (1) and 28 Dead (1) 
muromonab-C03 (0) viremia (0) 
Corticosteroids (5) and Bacteremia (1) and 134 Alive (1) 
muromonab-CD3 (0) viremia (0) 
tients. All 6 patients were ventilator dependent for pro-
longed periods. and 5 were hemodialysis dependent. A 
brain abscess caused by Aspergillus sp disseminated 
from primary pulmonary invasion in 4 patients and by 
direct extension from a mastoid sinusitis in 1 patient. 
No primary site of invasion was identified in 1 patient 
(Table 2). 
MEDICAL AND SURGICAL THERAPY 
Despite the administration oflow-dose prophylactic am-
photericin B (0.25-0.3 mglkg per day) fungal brain ab-
scesses (caused by Aspergillus or Candida sp or by mu-
cormycosis) developed in 10 of 24 patients (9 liver and 
1 kidney recipient). We estimate that this figure repre-
sents approximately 20% of the total patients who re-
ceived prophylactic amphotericin B. Of the 24 patients, 
19 received therapeutic doses (ie, 0.75-1 mglkg per day) 
of intravenous amphotericin B after diagnosis, 1 re-
ceived intravenous and intrathecal amphotericin B. and 
4 were treated \\;th intravenous amphotericin B and by 
brain abscess drainage. 
The remaining 4 recipients with nonfungal brain ab-
scesses (caused by Socardia and Toxoplasma sp) were 
treated with intravenous and oral antibiotic combina-
tions: in the 2 patients with a brain abscess caused by 
.\'acardia sp, excision of the chest wall lesions was per-
formed. 
SURVIVAL 
Of 28 patients. 24 died. for an overall mortality of 86%. 
Two (8.3 % ) of the 24 patients with a fungal brain ab-
scess in this study survived. while 2 (50%) of the pa-
tients with a nonfungal bralll abscess survived. Both pa-
tients with an abscess caused by Toxoplasma sp died, while 
both patients infected Wlth Nocardia sp survived. An analy-
sis of the 4 survivors produced the following findings. A 
14-day-old pediatric liver recipient with aspergillosis was 
treated wlth intrathecal and intravenous amphotericin B 
and was still alive at the 64-rnonth follow-up visit. How-
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Table 2. Clinical Characteristics of Brain Abscessa by A1lograHed Organ Type 
KI~- ":1': .' 
~~"D·1-- --~~K<-~Di: 
No. of 111/01 
SUbseIiUII •. ' "" ·"KyKlflD~!:Di"· 
0peratJ0aI 
Liver (15) 1.8 livers per patient 9 . AspIrg/J1ussp (13); MUCOfIIes sp (1); 
and Toxoplasma sp (1) 
Heart and '1.1 Hearts per patient . 3 AsperpiJIus sp (4): flocartJla sp (2); 
heart-lung {7} and Toxoplasma $II (1) 
Kidneys (6) 1.3 Kidneys per patient 5 Aspergillus sp IS) and Candida sp (1) Dead (S). -'1ve <lL . 
• The number in parentheses indicates the number of patients. 
ever. this patient has residual neurologic deficits and men-
tal retardation. 
A second liver recipient in whom a brain abscess 
caused by Candida sp developed was treated with drain-
age and intravenous amphotericin B and was alive with-
out residual neurologic deficits at the 146-month fol-
low-up visit. Two heart recipients with an abscess caused 
by Nocardia sp were treated with local chest wall exci-
sion and a combination of trimethoprim-sulfamethoxa-
zole and aminoglycoside antibiotics; they also survived 
their infection. 
Our pathologic definition of a brain abscess included 
all patients with infected localized intracerebral mass 
lesions. This dovetails well with the classification 
scheme of Conti and Rubin. i who categorized central 
nervous system infections after transplantation into 4 
clinical syndromes: acute meningitis, subacute-
chronic meningitis, meningoencephalitis, and focal 
brain dysfunction due to a localized mass lesion (ie, a 
brain abscess). 
Two clinical patterns emerged from our survey of 
this transplantation population that may change the thera-
peutic approach for these patients. First, a pyogenic bac-
terial brain abscess, commonly seen in immunocompe-
tent patients. did not occur in this population. This is 
most likely due to the fact that posttransplantation im-
munosuppression primarily impairs T-cell rather than B-
cell function. It has been observed in our series and other 
series5•7 that Aspergillus sp is the most common caus-
ative organism. followed by Toxoplasma gondii and 
Nocardia asteroides. 
Second and most importantly. there are 2 com-
pletely disparate groups within the transplantation 
population with regard to the timing, susceptibility. 
and predisposition for brain abscesses. This fact has im-
portant diagnostic and therapeutic implications. One 
group, which transcends allograft boundaries. includes 
those recipients who. shortly (median. 24 days in our 
series) after receiving induction therapy. have a postop-
erative course severely complicated by medical. surgi-
cal. and immunologic events. Fungi (ie. Aspergillus. 
Candida. and Mucorales sp) caused all of the abscesses 
in this setting and were resistant to any form of therapy. 
The second group consisted of the chronically immu-
nosuppressed although otherwise healthy recipients; 
abscesses caused by nonfungal organisms (ie, Nocardia 
and Toxoplasma sp) developed long (mean, 264 days) 
after transplantation. There may be some tendency to 
stratification by allograft type in this second group. par-
ticularly with Nocardia sp. which exclusively involved 
the heart transplant recipients in this series. 
FUNGAL BRAIN ABSCESSES 
Fungal brain abscesses in the transplantation popula-
tion most often arise by hematogenous dissemination 
from the lung.Sou Aspergillus sp are common respiratory 
pathogens with a 10% incidence of dissemination to the 
brain,13 most of which occur during the first 3 months 
after transplantation. 5. li An acute brain infarction or 
bleeding may be the earliest clue to the presence of a 
brain abscess caused by Aspergillus sp because of the or-
ganism's propensity to invade both large and small ce-
rebral vessels. producing thrombosis and consequently 
hemorrhagiC or ischemic infarcts. 1.8.15.16 Associated fun-
gal meningitis is rare and. therefore. cerebrospinal fluid 
smears and cultures for organisms are usually nega-
tiveK~·UK1T A CT scan usually reveals multiple low-den-
sity. nonenhancing lesions that are located most fre-
quently in the cerebrum and the basal ganglia.-I·17-19 The 
most reliable method of diagnosis remains biopsy with 
a histological examination and a culture. It is rarely 
treated successfully even when diagnosed after 
death,a.zo.zl possibly because of the virulence of the or-
ganism and its tendency to occlude blood vessels with 
consequent difficulty in the delivery of antifungal 
agents to infected brain tissue. 
Less commonly. abscesses caused by Candida and 
Mucorales sp arose under similar clinical circum-
stances. 
The systemic administration of treatment with full-
dose amphotericin B seems to be inadequate because of 
suboptimal penetration across the blood-brain barrier. 
Craniotomy with excision and/or drainagen .z6 for diag-
nostic and therapeutic purposes should play an active role 
in the treatment of these patients. The role of newer an-
tifungal agents. such as liposomal amphotericin B or itra-
conazole. is still unclear. 
The mortality of 91. 7% for patients with fungal 
brain abscesses in this series is similar to the 85% to 
100% mortality reported in the English-language litera-
ture.1.l3.l7-31 Even the administration of low-dose pro-
phylactic amphotericin B in 10 patients who were 
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deemed to be at higher risk did not completely prevent 
the development of fungal brain abscesses. However, 
the denominator of high-risk patients who received this 
low-dose therapy was difficult to determine, so it can-
not be stated that this form of therapy was entirely inef-
fective. Nevertheless, it seems that established central 
nervous system abscess formation is almost always fatal 
and that the survivors have a risk for serious.neurologic 
sequelae. 
The low frequency of fungal brain abscesses 
among all transplant recipients, and their complete ab-
sence in those chronically immunosuppressed although 
otherwise healthy outpatients, suggests that the viru-
lence of these organisms depends on proximate circum-
stances being present before a cerebral fungal abscess 
can occur. However, once multiple complicating factors 
(ie, subsequent operations, a retransplantation, hemo-
dialysis, or ventilator dependence) are present, and es-
pecially when pulmonary colonization occurs, then 
fungemia may be imminent. Because treatment with 
low-dose amphotericin B did not prevent the develop-
ment of a brain abscess in these cases, we would advo-
cate a trial of full-dose amphotericin B therapy for those 
patients deemed to be at high risk and who have pulmo-
nary colonization with Aspergillus sp. In conjunction, a 
reduction or cessation of immunosuppression will al-
low reinstitution of immune mechanisms and hopefully 
prevent abscess formation during this short-term medi-
cal period. 
NON FUNGAL BRAIN ABSCESS 
Nonfungal brain abscesses in transplant recipients also 
have unifying features: (1) They tend to occur in healthier 
patients at a long interval after transplantation when the 
patients are essentially recovered. In this sense, they re-
semble the typical opportunistic pneumonias (ie, Le-
gionella and Pneumocystis sp) and delayed cryptococcal 
meningitis. (2) The onset is fairly insidious but pursues 
a rather fulminant course once objective symptomatol-
ogy is present. (3) There may be some stratification by 
allograft type .... ith heart recipients being at highest risk. 
(4) Effective medical therapy does exist and should be 
empirical until diagnostic or therapeutic drainage pro-
vides a specifiC organism 
A brain abscess caused by Nocardia sp usually 
takes the form of a Single rather than multiple brain ab-
scesses or meningitis] Because cerebrospmal fluid and 
serological tests have not been found to be helpful. di-
agnosis is often made by presumption. particularly in 
patients with known nocardiallung or soft tlssue infec-
tions and abnormal neurologiC and/or CT scan hnd-
mgsY2 A brain abscess caused by Toxoplasma sp fre-
quently presents as an intracranial mass lesion and 
seizures, although the absence of symptoms is not un-
common.33H Unlike abscesses caused by Nocardia sp. 
posltlve results of serological tests and tissue examina-
tions are diagnosl1c. Reports in the literature have de-
scribed Toxoplasma sp brain dissemination from a do-
nated heartIg~ spread from activation of latent infection 
in experimental animals, and transmission by transfu-
sion of whole blood cells.J6 
Sulfonamides have been established to be effective 
if rapidly instituted in patients with a nonfungal brain 
abscess because the minimum inhibitory concentration 
is readily achievable with good penetration across the 
blood-brain barrier. Computed tomography-guided 
stereotactic aspiration or an open craniotomy and 
drainage are recognized as adjunctive to medical 
therapy.37.39 
Our overall mortality for patients with a nonfungal 
brain abscess was 50%. Both heart recipients ·wlth a brain 
abscess caused by Nocardia sp in our series survived the 
infection, which is in stark contrast with the mortality 
of 75% to 90% reported in the literature.-IO·41 This is prob-
ably due to early diagnosis and prompt treatment of the 
infected patients. 
-------1.'.4·4,,,&.1-------
The epidemiological features of brain abscess formation 
after solid organ transplantation suggest 2 populations 
of at-risk patients who are distinct in time, clinical set-
ting, and therapeutic approach. For the chronically im-
munosuppressed outpatient, an established brain ab-
scess should be empirically treated to manage Nocardia 
and Toxoplasma sp infections until tissue diagnOSiS is 
available. On the other hand, the acutely immunosup-
pressed posttransplantation recipient with high medical 
acuity is at high risk for the formation of a fungal brain 
abscess. There is no effective therapy, but frequent sur-
veillance for pulmonary colonization should be per-
formed. Should Aspergillus sp be found in these pa-
tients, it should be treated with therapeutiC doses of 
amphotericin B. In both types of abscess formation, sur-
gical intervention to confirm an empirical diagnosis or 
to drain amenable lesions is valuable. 
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JAMA 
Association of Small Low-Density lipoprotein Particles With the Incidence of Coronary Artery Disease 
in Men and Women 
Christopher D. Gardner, PhD; Stephen P. Fortmann, MD; Ronald M, Krauss, MD 
Objective.-To investigate the prospective association of low-density lipoprotein (LDL) particle diameter with the inci-
dence of fatal and nonfatal coronary artery disease (CAD). 
Design.-A nested case-control study. 
Setting,-Cases and controls were identified from a population-based sample of men and women combining all of the 5 
cross-sectional surveys conducted from 1979 to 1990 of the Stanford Five-City Project (FCP). 
Participants.-Incident CAD cases were identified through FCP surveillance between 1979 and 1992. Controls were matched 
by sex, 5-year age groups, survey time pOint, ethnicity, and FCP treatment condition. The sample included 124 matched 
pairs: 90 pairs of men and 34 pairs of women, 
Main Outcome Measures.-LDL peak particle diameter (LDL size) was detennined by gradient gel electrophoresis on plasma 
samples collected during the cross·sectional surveys (stored at 70°C for 5-15 years). Established CAD risk-factor data were 
available from FCP baseline measurements. 
Resuits,-LDL size was smaller among CAD cases than controls (mean:::':SD) (26.17:::': 1.00 nm vs 26.68:::': 0.90 nm; P<.OOl). 
The association was graded across control quintiles of LDL size. The Significant case-control difference in LDL size was in-
dependent of levels of high -density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), triglyceride, smok-
ing, systolic blood pressure, and body mass index, but was not significant after adjusting for the ratio of total cholesterol 
(TC) to HDL-C (TC:HDL-C). Among all the phYSiological risk factors, LDL size was the best differentiator of CAD status in 
conditional logistic regression. However, when added to the phYSiological parameters above, the TC:HDL-C ratio was found 
to be a stronger independent predictor of CAD status. 
Conclusion.-LDL size was SIgnificantly smaller in CAD cases than in controls in a prospective, population-based study. 
These findings support other evidence of a role for small, dense LDL particles in the etiology of atherosclerosis. (jAMA. 
1996;276:875-881) 
Reprints: Stephen P. Fonmann, MD, Stanford CenUr for Research in Disease Prevention, Stanford University School of Medi-
cine, 1000 Welch Rd, Palo Alto, CA 94304-1825 . 
. ~oCe SlJRGNOL 132. MAR 1997 
310 
